Drug Combination Details
| General Information of the Combination (ID: C34768) | |||||
|---|---|---|---|---|---|
| Name | Triptolide NP Info | + | Cytarabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | CHK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | H2AFX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | RAD53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NALM-6 | CVCL_0092 | Adult B acute lymphoblastic leukemia | Homo sapiens | ||
| In-vivo Model | To generate a mouse model of araC-resistant ALL, NALM-6/R cells (5 * 105) were subcutaneously injected into the angular veins of sublethally irradiated adult NSI (NOD/SCID IL2rg-/-) mice (20-30 g body weight, 2-3 months of age). | |||||
| Experimental
Result(s) |
Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption. | |||||
